ORYZF News and Press, Oryzon Genomics S.A. From 12/09/25

100% Overall response rate (ORR) in triple combo study with azacitidine and venetoclax in newly diagnosed AML patients 80% CR and 90% Composite Complete Remissions (CCR); median OS not reached after 9 months and good tolerability 70% of patients derived to Hematopoietic Stem Cell ...

2025-11-07 14:37:01 ET More on Oryzon Genomics S.A. Seeking Alpha’s Quant Rating on Oryzon Genomics S.A. Historical earnings data for Oryzon Genomics S.A. Financial information for Oryzon Genomics S.A. Read the full article on Seeking Alpha For...

The net result as of September 30, 2025 improved by $1.1M compared to September 2024, following termination of a Convertible Bonds financing facility with Nice&Green MADRID and CAMBRIDGE, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), ...

Three iadademstat abstracts have been accepted for presentation at the upcoming ASH-2025 Annual Meeting Preliminary data from the ongoing Phase Ib trial combining iadademstat with azacitidine and venetoclax in newly diagnosed, unfit AML patients showed a 100% overall response rate ...

Recently approved by the European Medicines Agency, RESTORE will evaluate iadademstat’s ability to raise fetal hemoglobin (HbF) in adult patients with SCD Iadademstat has demonstrated a favorable safety and tolerability profile across ~200 patients in prior oncology clinical trials...

MADRID, Spain and CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, announced today that its management will participate at the following upcoming events: BIO...

To enhance and accelerate regulatory dialogue with the FDA To provide strategic guidance across clinical development programs To bring deep expertise in CNS and immuno-oncology MADRID and CAMBRIDGE, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN C...

Provides clarity on the aspects to incorporate Company to address them and resubmit revised protocol MADRID, Spain and CAMBRIDGE, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, BME: ORY), a clinical-stage biopharmaceutical company a...

MADRID and CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and European leader in epigenetics, today announced that the European Patent Office (EPO) has issued a Decision to Grant for its patent a...

MADRID and CAMBRIDGE, Mass., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today that its management will participate at the following upcoming events: Drug ...